Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study.

Veronika Fedirko, Emory University
Hao Quang Tran, Georgia State University
Andrew Gewirtz, Emory University
Magdalena Stepień, International Agency for Research on Cancer
Antonia Trichopoulou, Hellenic Health Foundation
Krasimira Aleksandrova, German Institute of Human Nutrition
Potsdam-Rehbruecke
Anja Olsen, Danish Cancer Society Research Center
Anne Tjønneland, Danish Cancer Society Research Center
Kim Overvad, Aarhus University
Franck Carbonnel, Université Paris-Sud

Journal Title: BMC Medical Education
Volume: Volume 15, Number 1
Publisher: BioMed Central | 2017-04-04, Pages 72-72
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/s12916-017-0830-8
Permanent URL: https://pid.emory.edu/ark:/25593/s0zn9

Final published version: http://dx.doi.org/10.1186/s12916-017-0830-8

Copyright information:
© The Author(s). 2017

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed July 27, 2023 5:25 PM EDT
Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study

Veronika Fedirko 1,2*, Hao Quang Tran 3, Andrew T. Gewirtz 3, Magdalena Stepien 4, Antonia Trichopoulou 5,6, Krasimira Aleksandrova 7, Anja Olsen 8, Anne Tjønneland 8, Kim Overvad 9, Franck Carbonnel 10,11,12, Marie-Christine Boutron-Ruault 11,12, Gianluca Severi 10,11,13,14, Tilman Kühn 15, Rudolf Kaaks 15, Heiner Boeing 16, Christina Bamia 5,6, Pagona Lagiou 5,6,17, Sara Grioni 18, Salvatore Panico 19, Domenico Palli 20, Rosario Tumino 21, Alessio Naccarati 22, Petra H. Peeters 23, H. B. Bueno-de-Mesquita 24,25,26,27, Elisabete Weiderpass 28,29,30,31, José María Huerta Castaño 32,33, Aurelio Barricarte 33,34,35, María-José Sánchez 33,36, Miren Dorronsoro 33,37, J. Ramón Quiros 38, Antonio Agudo 39, Klas Sjöberg 40,41, Bodil Ohlsson 42, Oskar Hemmingsson 43, Mårten Werner 44, Kathryn E. Bradbury 45, Kay-Tee Khaw 46, Nick Wareham 47, Konstantinos K. Tsilidis 48,49, Dagfinn Aune 49, Augustin Scalbert 4, Isabelle Romieu 4, Elio Riboli 5,6 and Mazda Jenab 4*

Abstract

Background: Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede the development of liver cancer. However, human studies, particularly from prospective settings, are lacking.

Methods: We used a case-control study design nested within a large prospective cohort to assess the association between circulating levels of anti-lipopolysaccharide (LPS) and anti-flagellin immunoglobulin A (IgA) and G (IgG) (reflecting long-term exposures to LPS and flagellin, respectively) and risk of hepatocellular carcinoma. A total of 139 men and women diagnosed with hepatocellular carcinoma between 1992 and 2010 were matched to 139 control subjects. Multivariable rate ratios (RRs), including adjustment for potential confounders, hepatitis B/C positivity, and degree of liver dysfunction, were calculated with conditional logistic regression.

Results: Antibody response to LPS and flagellin was associated with a statistically significant increase in the risk of hepatocellular carcinoma (highest vs. lowest quartile: RR = 11.76, 95% confidence interval = 1.70–81.40; Ptrend = 0.021). This finding did not vary substantially by time from enrollment to diagnosis, and did not change after adjustment for chronic infection with hepatitis B and C viruses.

Conclusions: These novel findings, based on exposures up to several years prior to diagnosis, support a role for gut-derived bacterial products in hepatocellular carcinoma development. Further study into the role of gut barrier failure and exposure to bacterial products in liver diseases is warranted.

Keywords: Hepatocellular carcinoma, Lipopolysaccharide, Flagellin, Endotoxins, Prospective studies

* Correspondence: vfedirk@emory.edu; jenabm@iarc.fr
Veronika Fedirko and Mazda Jenab are joint corresponding authors.

1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
2Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France
Full list of author information is available at the end of the article
Background
Hepatocellular carcinoma (HCC) has several established risk factors, namely chronic infection with hepatitis B and/or C viruses (HBV/HCV), aflatoxin exposure, diabetes, obesity, smoking, and high alcohol consumption [1]. Recent observations from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort also show a role for dietary and lifestyle exposures in HCC development [2–6] and indicate metabolic differences between cases and controls [7–9]. Other observations suggest that many of these same factors can weaken the colonic epithelial barrier function [10–12], allowing the translocation of toxic bacterial products such as lipopolysaccharide (LPS; also known as endotoxin, an integral part of the outer membrane of Gram-negative bacterial cell walls) and flagellin (the primary structural component of flagella). Overabundance of bacterial LPS from the gut microbiota may trigger chronic inflammation and higher oxidative stress [13]. Since these bacterial cell components are transported to the liver through the portal vein, it has been suggested that they drive the development of metabolic and liver diseases. In fact, animal data suggest that exposure to LPS or flagellin can produce liver inflammation, liver injury, or steatohepatitis [14–16], while human data indicate higher circulating LPS in patients with chronic liver diseases predisposing to HCC (non-alcoholic fatty liver disease [NAFLD] and non-alcoholic steatohepatitis [NASH]) [17–24]. However, despite a probable role of gut-derived bacterial products in the pathogenesis and progression of liver disease, no epidemiologic studies to date have investigated the association between biomarkers of LPS and flagellin and risk of HCC. In consideration of these points, in a first study of its kind, we investigate whether prediagnostic serum anti-LPS- and anti-flagellin-specific immunoglobulin A and G (IgA and IgG) levels are associated with HCC risk within EPIC, a large cohort of geographically diverse Western European populations.

Methods
Study design
EPIC is a multicenter prospective cohort study designed to investigate the association between lifestyle and environmental factors and cancer incidence. The rationale and study design are described in detail elsewhere [25]. The study subjects were recruited from the general population, except for Utrecht and Florence (women attending breast cancer screening), the Oxford “Health conscious” subcohort (half are vegetarian), and subsamples of the Italian and Spanish cohorts (blood donors). Lifestyle data were collected from approximately 520,000 men and women aged 20–85 years enrolled between 1992 and 2000 in 23 centers throughout 10 European countries. At recruitment, blood samples were collected from most participants and are stored at the International Agency for Research on Cancer (IARC, Lyon, France) in –196 °C liquid nitrogen for all countries except Denmark (–150 °C, nitrogen vapor) and Sweden (–80 °C, freezers). Approval for this study was obtained from the IARC Ethics Committee (Lyon, France) as well as from participating EPIC centers.

Follow-up for cancer incidence
Cancer incidence was determined through record linkage with population-based regional cancer registries (Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the UK; complete up to December 2008) or via a combination of methods (health insurance records, contacts with cancer/pathology registries, active follow-up through study subjects and next of kin; France, Germany, Greece; complete until June 2010).

The nested case-control study
Ascertainment of case patients and selection of controls
HCC was defined as first incident tumor in the liver (C22.0 as per the 10th Revision of the International Statistical Classification of Diseases, Injury and Causes of Death [ICD-10]). For each identified case, the histology, the methods used to diagnose the cancer, and α-fetoprotein levels were reviewed to exclude metastatic cases or other types of liver cancers as described previously [2]. During the period between recruitment and 2010, a total of 204 HCC cases were identified. Sixty-five cases had no available serum samples (including 21 cases diagnosed after 2006 in Malmö, Sweden, and Denmark and excluded for administrative reasons and lack of biosample availability) and were not included in the analysis; however, they did not differ by lifestyle and demographic characteristics from cases with available serum samples. For each case, one control was selected by incidence density sampling from all cohort members alive and free of cancer (except non-melanoma skin cancer), and matched by age at blood collection (±1 year), sex, center, date (±2 months)/hour (±3 h) of blood collection, fasting status at blood collection (<3/3–6/>6 h); additionally among women, menopausal status (pre-/peri-/postmenopausal) and hormone replacement therapy use at blood collection (yes/no). The final sample size included 139 HCC cases and 139 matched controls.

Laboratory biomarker measures for serum anti-LPS- and anti-flagellin-specific Ig levels
Serum anti-LPS- and anti-flagellin-specific IgA and IgG levels were quantitated by enzyme-linked immunosorbent assay (ELISA) at Georgia State University (Atlanta, GA, USA), as previously described [26–28]. Briefly, ELISA plates (Costar®) were coated overnight with
purified laboratory-made flagellin (100 ng/well; prepared from Salmonella typhimurium, strain SL 3201 fljB−/− as previously described [29]) or purified Escherichia coli LPS (2 µg/well; from E. coli 0128: B12, Sigma, Catalog No. 2887) in 9.6 pH bicarbonate buffer. Serum samples from cases and controls diluted 1:200 were applied to wells coated with flagellin or LPS. After incubation and washing, the wells were incubated either with anti-IgG coupled to horseradish peroxidase (GE, Catalog No. 375112) or, in the case of IgA-specific antibodies, with horseradish peroxidase-conjugated anti-IgA (KPL, Catalog No. 14-10-01). Using the established platform, specificity of anti-flagellin/LPS Igs is observed when the signal is extremely low when using serum from germ-free mice and completely abolished using serum from RAG-1 knockout mice and germ-free mice on an elemental diet. The specificity of the anti-human IgA and anti-human IgG is in accordance with manufacturer’s specifications. Quantitation of total immunoglobulins was performed using the colorimetric peroxidase substrate tetramethylbenzidine (TMB), and the optical density (OD) was read at 450 nm and 540 nm (the difference was taken to compensate for optical interference from the plate) with an ELISA plate reader. Data are reported as OD corrected by subtracting background (determined by readings in blank samples) and are normalized to each plate’s control sample, which was prepared in bulk, aliquoted, frozen, and thawed daily as used. Standardization was performed using preparations of known concentrations of IgA and IgG. Matched case-control pairs were handled identically and assayed in the same batch in a blinded fashion. A very low coefficient of variation (CV <5%) between duplicates based on previous assays [30] permitted singleton sample analysis. Based on three positive control samples included in each plate, mean inter-assay CVs were 2.2%, 2.5%, 3.4%, and 4.8% for anti-LPS IgG, anti-flagellin IgA, anti-LPS IgA, and anti-flagellin IgG, respectively. The between-batch CVs were 9.3%, 12.7%, 16.2%, and 11.3% for anti-flagellin IgA, anti-flagellin IgG, anti-LPS IgA, and anti-LPS IgG, respectively.

**Laboratory assays of HBV/HCV status, biomarkers of liver injury, and hsCRP**

The present analysis included existing biomarker data for the same set of cases and matched controls [2, 7, 9]. For a total of 100 of the HCC cases (those diagnosed before 2006) and their matched controls, existing data were available for HBV/HCV seropositivity (ARCHITECT HBsAg and anti-HCV chemiluminescent microparticle immunoassays; Abbott Diagnostics, France) and biomarkers of hepatic injury (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT], liver-specific alkaline phosphatase [AP], albumin, total bilirubin, and total protein; ARCHITECT c Systems™; Abbott Diagnostics) [2]. We created the liver damage score by summarizing the number of abnormal values for six liver function tests (ALT > 55 U/L, AST > 34 U/L, GGT men >64 U/L, GGT women >36 U/L, AP >150 U/L, albumin <35 g/L, total bilirubin >20.5 µmol/L; cut-points were provided by the laboratory and were based on assay specifications; range from 0 to 6).

Serum amino acids were measured for all 139 cases and 139 matched controls using the Biocrates AbsoluteIDQ p150 mass spectrometry kit (Biocrates Life Science AG, Innsbruck, Austria) on a QTRAP mass spectrometer (IARC, Lyon, France) [9]. Fischer’s ratio was calculated as the molar ratio of branched-chain amino acids (leucine + valine + isoleucine) to aromatic amino acids ([phenylalanine + tyrosine + histidine + tryptophan] or [phenylalanine + tyrosine]) and was used as an indicator of hepatic functional reserve and severity of liver dysfunction [31, 32]. High-sensitivity C-reactive protein (hsCRP) was measured using a high-sensitivity assay on a Turbidimetric Modular system (Roche, Mannheim, Germany) [7].

**Statistical analyses**

No transformations were used for all biomarkers because they were normally distributed. Differences in concentrations of biomarkers among the controls by baseline characteristics were examined by analysis of variance. P values for tests of trend (for ordinal variables) or of heterogeneity were reported. Four conditional logistic models were used to assess the strengths of association (incidence rate ratio [IRR] as estimated by odds ratio [OR] [33] with 95% confidence interval (CI) and tests for trend): (1) with matching factors only, (2) with adjustment for potential confounders (smoking status [never, former, current], body mass index [continuous], baseline alcohol intake [continuous], coffee intake [continuous], lifetime alcohol drinking pattern [always heavy, periodically heavy, former heavy, never heavy, former light, light, and never drinkers], physical activity [active, moderately active, moderately inactive, inactive], and level of education [none, primary school, secondary school, more than secondary school, not specified]), and (3) with additional adjustment for Fischer’s ratio (molar ratio of branched-chain amino acids [leucine +valine + isoleucine] to aromatic amino acids [phenylalanine + tyrosine + histidine + tryptophan]); inversely related to severity of liver dysfunction, with lower values of the ratio indicating a more severe liver dysfunction [31, 32]. Serum anti-LPS and anti-flagellin immunoglobulin levels were included individually and in the following logical combinations in models as continuous (per unit increase; approximately equal to 1 standard deviation for each individual biomarker) and as
categorical variables, with quartile cut-points based on the distribution in the control subjects: (1) total anti-LPS = anti-LPS IgG + anti-LPS IgA (total exposure to LPS); (2) total anti-flagellin = anti-flagellin IgG + anti-flagellin IgA (total exposure to flagellin); (3) anti-LPS and anti-flagellin IgG = anti-LPS IgG + anti-flagellin IgG (all IgGs, indicating possible systemic response to endotoxins [34]); (4) anti-LPS and anti-flagellin IgA = anti-LPS IgA + anti-flagellin IgA (all IgAs, indicating possible mucosal response to endotoxins [34]); (5) anti-LPS flagellin = anti-LPS IgG + anti-flagellin IgG + anti-LPS IgA + anti-flagellin IgA (total exposure to LPS and flagellin). To test dose responses, trend variables were assigned the median values for each quartile of biomarker.

To partly control for potential pre-existing liver dysfunction, in the multivariable model, we also performed additional adjustment for and stratification by HBV/HCV status and “liver damage score” by summarizing the number of abnormal values for six liver function tests (categorized as 0 = no liver injury, 1–2 = possible minor injury, ≥3 = possible injury; see Additional file 1: Table S1 and Table 4 footnote).

Effect modification on the multiplicative scale for potential biologically plausible effect modifying variables (sex, age at diagnosis, body mass index [BMI, normal vs. overweight/obese], prevalent type 2 diabetes [yes vs. no; data available for a subset of subjects only], smoking [never vs. former/current], lifetime alcohol drinking pattern [ever heavy vs. light/never]) was tested by including interaction terms formed by the product of modifying variable categories and the value of categories of exposure of interest. The statistical significance of interactions was assessed using likelihood ratio tests based on the models with and without the interaction terms.

All statistical tests were two-sided, and P values <0.05 were considered statistically significant. Analyses were conducted using the SAS version 9.2 (SAS Institute, Cary, NC, USA) statistical package.

Results
Baseline characteristics of participants
HCC cases were diagnosed, on average, 6 years (standard deviation = 3.4) after blood collection and had a greater proportion of current smokers and a greater prevalence of diabetes than controls (Table 1). The mean serum concentration of total anti-LPS and anti-flagellin Igs was higher in HCC cases vs. controls (8.08 vs. 6.86, P < 0.001). No difference in total anti-LPS and anti-flagellin Ig levels by HBV/HCV status was observed for both HCC cases (P = 0.379) and controls (P = 0.722). The Fischer ratio was lower in HCC cases vs. controls (1.33 vs. 1.53, P < 0.001) and, among cases, moderately inversely correlated with total anti-LPS and anti-flagellin Igs (r = −0.28, P < 0.001). Among cases, having potential liver dysfunction as indicated by a liver damage score value ≥3 was associated with higher levels of total anti-LPS and anti-flagellin Igs among cases (P < 0.001 compared to cases with a liver damage score value of 0).

Lifestyle and dietary factors associated with anti-LPS and anti-flagellin Igs in controls
Among controls, concentrations of biomarkers did not differ statistically significantly by sex, age at blood collection (Table 2), and other factors (Additional file 1: Table S2). A higher BMI was associated with higher concentrations of anti-LPS Igs (P = 0.02), anti-LPS and anti-flagellin IgGs (P = 0.02), and total anti-LPS and anti-flagellin (P = 0.04). Similar patterns were observed for waist-to-hip ratio, a measure of central adiposity, and CRP, a biomarker of chronic systemic inflammation, although they were not statistically significant.

Associations of serum anti-LPS and anti-flagellin Igs with risk of HCC
The associations between LPS and flagellin biomarkers with risk of HCC are presented in Table 3 (for logical combination of biomarkers) and Additional file 1: Table S3 (for individual biomarkers). All analysis models showed a statistically significant positive association between high anti-LPS and anti-flagellin Ig levels and HCC risk (for total anti-LPS and anti-flagellin Igs, highest vs. lowest quartiles, matching factors model: IRR = 8.72, 95% CI: 2.78–27.29; most adjusted multivariable model with Fischer’s ratio: IRR = 11.76, 95% CI: 1.70–81.40, Ptrend = 0.021).

Effect modifications and sensitivity analyses
For all variables tested, no statistically significant effect modification were observed (all P >0.26), except for sex, which demonstrated as borderline nonsignificant (Table 4; P values for interaction by sex ≥0.03, see the footnotes). However, the number of women in the study was much smaller compared to the number of men. We also checked the consistency of our results after the exclusion of the cases diagnosed during the first 2 and 4 years of follow-up to exclude possible reverse causation, since the participants might have modified their diet and/or lifestyle before enrollment due to prediagnostic symptoms. The estimates did not change considerably after these exclusions or in analyses stratified by follow-up time. The magnitude of the effect estimates did not change substantially after excluding persons with positive HBV/HCV status (data not shown) or by further adjustment for HBV/HCV status and liver damage score (Table 4).
In this case-control study nested within a large prospective cohort, we observed a statistically significant positive association between prediagnostic serum concentrations of anti-LPS and anti-flagellin Igs and risk of HCC. The strength of the association did not vary substantially by time from enrollment to diagnosis and was only modestly impacted by adjustment for various lifestyle factors and markers reflecting pre-existing liver damage. These findings provide the first prospective epidemiologic evidence on the topic and add to the existing experimental data showing that weakened gut barrier function and subsequent exposure to bacterial products may promote hepatocarcinogenesis [13, 35].

Higher circulating levels of anti-LPS and anti-flagellin Igs are thought to be indicative of chronic exposure to...
| Characteristic          | Anti-LPS IgG + IgA 95% CI | Anti-Flagellin IgG + IgA 95% CI | Anti-LPS IgG + Anti-Flagellin IgA 95% CI | Anti-LPS IgA 95% CI | Anti-LPS IgA + IgA + Anti-Flagellin IgG + IgA 95% CI |
|------------------------|---------------------------|---------------------------------|------------------------------------------|---------------------|---------------------------------------------------|
| **Sex**                |                           |                                 |                                          |                     |                                                   |
| Female                 | 3.78                      | 3.37                            | 4.19                                     | 3.18                | 3.54                                             |
|                        |                           |                                 |                                          | 3.37                | 3.59                                             |
|                        |                           |                                 |                                          | 3.15                | 4.02                                             |
|                        |                           |                                 |                                          | 6.96                | 6.23                                             |
|                        |                           |                                 |                                          |                     | 7.68                                             |
| Male                   | 3.58                      | 3.32                            | 3.85                                     | 3.24                | 3.48                                             |
|                        |                           |                                 |                                          | 3.11                | 3.71                                             |
|                        |                           |                                 |                                          | 3.43                | 3.99                                             |
|                        |                           |                                 |                                          | 6.82                | 6.35                                             |
|                        |                           |                                 |                                          |                     | 7.29                                             |
| **P value**            | 0.425                     | 0.771                           | 0.249                                    | 0.639               | 0.762                                            |
| **Age at blood collection, years** |                   |                                 |                                          |                     |                                                   |
| ≤55                    | 3.64                      | 3.21                            | 4.07                                     | 3.11                | 3.49                                             |
|                        |                           |                                 |                                          | 3.26                | 3.65                                             |
|                        |                           |                                 |                                          | 3.02                | 3.94                                             |
|                        |                           |                                 |                                          | 6.75                | 5.97                                             |
|                        |                           |                                 |                                          |                     | 7.52                                             |
| 55.1–60                | 3.40                      | 2.93                            | 3.87                                     | 3.24                | 3.66                                             |
|                        |                           |                                 |                                          | 2.99                | 3.42                                             |
|                        |                           |                                 |                                          | 3.15                | 4.14                                             |
|                        |                           |                                 |                                          | 6.64                | 5.80                                             |
|                        |                           |                                 |                                          |                     | 7.47                                             |
| 60.1–65                | 3.56                      | 3.15                            | 3.96                                     | 3.13                | 3.48                                             |
|                        |                           |                                 |                                          | 3.10                | 3.75                                             |
|                        |                           |                                 |                                          | 3.16                | 4.01                                             |
|                        |                           |                                 |                                          | 6.68                | 5.96                                             |
|                        |                           |                                 |                                          |                     | 7.40                                             |
| >65                    | 4.01                      | 3.53                            | 4.48                                     | 3.48                | 3.90                                             |
|                        |                           |                                 |                                          | 3.44                | 3.86                                             |
|                        |                           |                                 |                                          | 3.55                | 4.56                                             |
|                        |                           |                                 |                                          | 7.49                | 6.64                                             |
|                        |                           |                                 |                                          |                     | 8.34                                             |
| **P value**            | 0.218                     | 0.270                           | 0.499                                    | 0.131               | 0.215                                            |
| **BMI, kg/m²**         |                           |                                 |                                          |                     |                                                   |
| ≤25                    | 3.39                      | 2.98                            | 3.79                                     | 3.02                | 3.38                                             |
|                        |                           |                                 |                                          | 3.04                | 3.40                                             |
|                        |                           |                                 |                                          | 2.93                | 3.80                                             |
|                        |                           |                                 |                                          | 6.41                | 5.68                                             |
|                        |                           |                                 |                                          |                     | 7.13                                             |
| 25.1–29.9              | 3.55                      | 3.23                            | 3.87                                     | 3.24                | 3.52                                             |
|                        |                           |                                 |                                          | 3.03                | 3.75                                             |
|                        |                           |                                 |                                          | 3.41                | 4.09                                             |
|                        |                           |                                 |                                          | 6.78                | 6.21                                             |
|                        |                           |                                 |                                          |                     | 7.35                                             |
| ≥30                    | 4.11                      | 3.67                            | 4.55                                     | 3.44                | 3.83                                             |
|                        |                           |                                 |                                          | 3.67                | 4.06                                             |
|                        |                           |                                 |                                          | 3.41                | 4.35                                             |
|                        |                           |                                 |                                          | 7.55                | 6.76                                             |
|                        |                           |                                 |                                          |                     | 8.34                                             |
| **P value**            | 0.019                     | 0.123                           | 0.022                                    | 0.114               | 0.036                                            |
| **Waist-to-hip ratio (WHR)** |                       |                                 |                                          |                     |                                                   |
| <0.92 (M)/<0.77 (W)     | 3.35                      | 2.98                            | 3.73                                     | 3.15                | 3.49                                             |
|                        |                           |                                 |                                          | 2.98                | 3.49                                             |
|                        |                           |                                 |                                          | 2.98                | 3.32                                             |
|                        |                           |                                 |                                          | 3.53                | 3.98                                             |
|                        |                           |                                 |                                          | 6.50                | 5.83                                             |
|                        |                           |                                 |                                          |                     | 7.18                                             |
| 0.92–0.97 (M)/0.77–0.84 (W) | 3.77                    | 3.41                            | 4.14                                     | 3.21                | 3.54                                             |
|                        |                           |                                 |                                          | 3.27                | 3.60                                             |
|                        |                           |                                 |                                          | 3.72                | 4.11                                             |
|                        |                           |                                 |                                          | 6.99                | 6.33                                             |
|                        |                           |                                 |                                          |                     | 7.64                                             |
| >0.97 (M)/>0.84 (W)     | 3.80                      | 3.40                            | 4.20                                     | 3.31                | 3.67                                             |
|                        |                           |                                 |                                          | 3.34                | 3.70                                             |
|                        |                           |                                 |                                          | 3.35                | 4.21                                             |
|                        |                           |                                 |                                          | 7.12                | 6.40                                             |
|                        |                           |                                 |                                          |                     | 7.83                                             |
| **P value**            | 0.110                     | 0.510                           | 0.153                                    | 0.401               | 0.221                                            |
| **CRP, mg/L**          |                           |                                 |                                          |                     |                                                   |
| ≤1                     | 3.40                      | 3.03                            | 3.76                                     | 3.09                | 3.42                                             |
|                        |                           |                                 |                                          | 3.02                | 3.36                                             |
|                        |                           |                                 |                                          | 3.46                | 3.86                                             |
|                        |                           |                                 |                                          | 6.48                | 5.82                                             |
|                        |                           |                                 |                                          |                     | 7.14                                             |
| 1–5                    | 3.68                      | 3.25                            | 4.12                                     | 3.39                | 3.78                                             |
|                        |                           |                                 |                                          | 3.27                | 3.66                                             |
|                        |                           |                                 |                                          | 3.80                | 4.27                                             |
|                        |                           |                                 |                                          | 7.07                | 6.29                                             |
|                        |                           |                                 |                                          |                     | 7.85                                             |
| >5                     | 3.95                      | 3.36                            | 4.53                                     | 3.33                | 3.86                                             |
|                        |                           |                                 |                                          | 3.17                | 4.10                                             |
|                        |                           |                                 |                                          | 4.10                | 4.74                                             |
|                        |                           |                                 |                                          | 7.28                | 6.23                                             |
|                        |                           |                                 |                                          |                     | 8.32                                             |
| **P value**            | 0.098                     | 0.326                           | 0.493                                    | 0.077               | 0.156                                            |

*All P values are based on a test of linear trend, except P values for heterogeneity by sex, smoking status, and lifetime alcohol drinking pattern.

*aAvailable for 100 controls.
bacterial products LPS and flagellin, which can elicit innate immune and inflammatory responses [36]. High exposure of the liver to these microbial products could be due to their translocation through the disrupted gut barrier, which could be a result of intestinal inflammation, chronic alcohol abuse, early phase hepatic injury, or dietary and/or lifestyle factors [24, 37, 38]. In fact, data from animal studies support an important role for gut microbiota in liver health and disease [13, 39]. Furthermore, patients with NAFLD and NASH, liver diseases that often precede HCC, demonstrate elevated circulating endotoxin levels, LPS, LPS-binding protein, and anti-LPS antibodies [17–24]. It is plausible that dietary and lifestyle factors associated with higher risk of cancer development, such as components of Western-type diets, instigate microbiome changes, favoring the relative abundance of Gram-negative bacteria, and thus leading to increased exposure to LPS. For example, studies in mice show that diets high in fructose or fat can alter gut barrier function, inducing endotoxemia and the development of liver steatosis [11, 40]. Similar observations have been made in humans [21] and for other factors such as obesity [12, 36, 41]. Although

| Biomarker | IRR (95% CI) | Q1 | Q2 | Q3 | Q4 | P \text{ trend} | OR per \text{1 unit} |
|-----------|--------------|----|----|----|----|----------------|-----------------|
| Anti-LPS IgG + IgA, n case/control | 20/35 | 25/34 | 35/35 | 59/35 | Ref. | 1.34 (0.61–2.98) | 2.74 (1.13–6.65) | 11.17 (3.46–36.00) | <0.0001 | 2.19 (1.59–3.03) |
| Multivariable | 1.64 (0.56–4.83) | 2.52 (0.76–8.39) | 17.16 (3.52–83.50) | 0.001 | 2.58 (1.65–4.03) |
| + dietary factors | 1.65 (0.54–5.04) | 2.67 (0.77–9.31) | 20.06 (3.88–103.0) | 0.001 | 2.68 (1.69–4.23) |
| + Fischer’s ratio | 2.52 (0.70–9.08) | 2.17 (0.55–8.63) | 13.65 (1.91–97.80) | 0.017 | 2.05 (1.25–3.36) |
| Anti-Flagellin IgG + IgA, n case/control | 22/34 | 25/36 | 37/35 | 55/34 | Ref. | 1.09 (0.5–2.38) | 2.35 (1.03–5.37) | 7.11 (2.46–20.55) | <0.0001 | 2.18 (1.56–3.06) |
| Multivariable | 1.05 (0.37–2.93) | 2.87 (1.00–8.20) | 7.78 (2.19–27.57) | 0.001 | 2.31 (1.51–3.54) |
| + dietary factors | 1.21 (0.40–3.59) | 3.07 (1.05–9.01) | 6.72 (1.88–24.02) | 0.003 | 2.25 (1.47–3.47) |
| + Fischer’s ratio | 1.52 (0.43–5.37) | 4.37 (1.21–15.84) | 3.59 (0.79–16.35) | 0.025 | 1.80 (1.12–2.90) |
| Anti-LPS IgG + Anti-Flagellin IgG, n case/control | 24/34 | 29/36 | 40/34 | 46/35 | Ref. | 1.23 (0.58–2.63) | 2.11 (0.99–4.52) | 4.08 (1.43–11.64) | 0.006 | 2.02 (1.43–2.85) |
| Multivariable | 1.40 (0.53–3.68) | 2.92 (1.06–8.06) | 5.80 (1.46–23.02) | 0.007 | 2.47 (1.56–3.91) |
| + dietary factors | 1.43 (0.52–3.92) | 3.45 (1.18–10.07) | 5.37 (1.31–22.10) | 0.007 | 2.57 (1.60–4.12) |
| + Fischer’s ratio | 1.18 (0.39–3.60) | 3.89 (1.12–13.58) | 2.71 (0.42–17.29) | 0.056 | 1.97 (1.15–3.36) |
| Anti-LPS IgA + Anti-Flagellin IgA, n case/control | 18/35 | 27/34 | 27/35 | 67/35 | Ref. | 2.16 (0.82–5.72) | 2.23 (0.85–5.87) | 8.47 (3.01–23.86) | <0.0001 | 1.83 (1.43–2.36) |
| Multivariable | 4.00 (0.96–16.63) | 4.91 (1.15–20.9) | 14.22 (3.02–66.90) | 0.001 | 1.99 (1.39–2.86) |
| + dietary factors | 5.34 (1.21–23.68) | 4.73 (1.06–21.16) | 14.97 (3.04–73.50) | 0.001 | 1.98 (1.37–2.86) |
| + Fischer’s ratio | 2.65 (0.55–12.84) | 4.49 (0.94–21.6) | 8.40 (1.64–43.12) | 0.009 | 1.65 (1.11–2.45) |
| Anti-LPS IgG + IgA + Anti-Flagellin IgG + IgA, n case/control | 23/34 | 22/35 | 37/35 | 57/35 | Ref. | 0.97 (0.46–2.08) | 2.25 (1.03–4.91) | 8.72 (2.78–27.29) | <0.0001 | 1.57 (1.31–1.88) |
| Multivariable | 1.54 (0.59–4.02) | 2.78 (0.94–8.21) | 14.01 (2.99–65.60) | 0.001 | 1.72 (1.34–2.21) |
| + dietary factors | 1.71 (0.63–4.68) | 2.78 (0.92–8.35) | 13.31 (2.78–63.70) | 0.002 | 1.71 (1.33–2.21) |
| + Fischer’s ratio | 1.75 (0.58–5.27) | 2.19 (0.63–7.66) | 11.76 (1.70–81.40) | 0.021 | 1.48 (1.13–1.94) |

\text{IRRs and 95% confidence intervals were estimated by conditional logistic regression conditioned on the matching factors.} 

\text{Base model further adjusted for smoking status (never, former, current), body mass index (continuous), baseline alcohol intake (continuous), coffee intake (continuous), lifetime alcohol drinking pattern (always heavy, periodically heavy, former heavy, never heavy, former light, light, and never drinker), physical activity (active, moderately active, moderately inactive, inactive), and level of education (none, primary school, secondary school, more than secondary school, not specified).} 

\text{Matching factors + dietary factors calculated as the molar ratio of branched-chain amino acids (leucine, valine, isoleucine) to aromatic amino acids (phenylalanine, tyrosine, histidine, tryptophan), an indicator of hepatic functional reserve and the severity of liver dysfunction.} 

Fedirko et al. BMC Medicine (2017) 15:72
there is some debate in the current animal literature as to whether endotoxemia is a cause or consequence of liver damage [24], it is becoming increasingly clear, as noted above, that it is involved in the development and progression of NAFLD [18]. Our results build on this knowledge to show a possible continued role for endotoxemia in HCC development.

The most compelling mechanism for this observation is bacterial dysbiosis (abundance of Gram-negative bacteria), breakdown of gut barrier function, and leakage of bacterial products across the gut lumen. Another potential mechanism could be increased intestinal LPS absorption (i.e., preferential incorporation of LPS into chylomicrons with long-chain dietary fatty acids [42]). Irrespective of the mechanisms leading to higher LPS exposure, the link between LPS and increased inflammation appears convincing [10]. LPS exposure activates the innate immune system by activating the toll-like receptor 4 (TLR4)-MD2 complex, which in turn through the myeloid differentiation primary response protein 88 (MYD88)-dependent and TIR domain-containing adaptor-inducing IFNβ (TRIF) (or MYD88-independent) pathways, induces the production of pro-inflammatory cytokines and interferon (IFN)-inducible proteins, respectively [43]. Thus, the chronic inflammation, oxidative stress, and insulin resistance states of obesity, chronic liver diseases, and, subsequently, HCC may be partly related to endotoxemia. Indeed, there is compelling evidence that obesity might lead to weakening of the gut barrier function and hence greater translocation of LPS [10]. Furthermore, both LPS and flagellin have been shown to induce pro-inflammatory responses in the gut and liver [29, 44–46]. In our study, although circulating anti-LPS or anti-flagellin concentrations increased with BMI, multivariable adjustment for BMI, multivariable adjustment for BMI and other perceived confounders (notably alcohol intake, alcohol drinking patterns, and smoking) did not attenuate our observed HCC risk associations with any of the anti-LPS or anti-flagellin biomarkers. Similarly, further adjustment by hsCRP did not appreciably alter our findings — although our single measure of hsCRP may not be sufficient to effectively assess local inflammatory states.

Another interesting observation in our study is a potential sex-specific effect, with a stronger HCC risk observed in men than in women, although the heterogeneity was

### Table 4
Incidence rate ratios (IRRs) and 95% confidence intervals (in parentheses) of hepatocellular carcinoma per 1 unit increase in serum anti-LPS and anti-flagellin immunoglobulins from analyses stratified according to selected characteristics and sensitivity analyses, EPIC study, 1992–2010

| Model                                      | Cases | Anti-LPS IgG + IgA | Anti-flagellin IgG + IgA | Anti-LPS IgG + anti-flagellin IgG | Anti-LPS IgA + anti-flagellin IgG | Anti-LPS IgG + IgA + anti-flagellin IgG + IgA |
|--------------------------------------------|-------|-------------------|--------------------------|-----------------------------------|----------------------------------|---------------------------------------------|
| Stratified analyses                        |       |                   |                          |                                   |                                  |                                             |
| By sex                                     |       |                   |                          |                                   |                                  |                                             |
| Men                                        | 98    | 5.12 (2.09–12.55) | 5.58 (2.11–14.78)        | 4.93 (2.06–11.79)                 | 2.34 (1.38–3.97)                 | 2.65 (1.58–4.45)                           |
| Women                                      | 41    | 1.61 (0.58–4.44)  | 1.54 (0.54–4.36)         | 1.21 (0.43–3.41)                  | 1.71 (0.72–4.03)                 | 1.34 (0.75–2.41)                           |
| P interaction by sex                       | 0.062 | 0.059             | 0.030                    | 0.402                             | 0.055                            |                                             |
| Cases diagnosed                            |       |                   |                          |                                   |                                  |                                             |
| >2 years since blood collection            | 117   | 2.75 (1.62–4.67)  | 2.04 (1.29–3.21)         | 2.35 (1.38–4.01)                  | 2.05 (1.33–3.15)                 | 1.68 (1.27–2.23)                           |
| >4 years since blood collection            | 97    | 4.87 (2.18–10.89) | 2.52 (1.4–5.4)           | 3.70 (1.64–8.34)                  | 2.52 (1.47–4.33)                 | 2.11 (1.41–3.15)                           |
| By follow-up timea                         |       |                   |                          |                                   |                                  |                                             |
| < 6 y since blood collection               | 65    | 2.45 (1.41–4.26)  | 2.17 (1.27–3.73)         | 2.43 (1.36–4.37)                  | 1.89 (1.20–2.95)                 | 1.67 (1.22–2.29)                           |
| ≥ 6 y since blood collection               | 74    | 3.16 (1.65–6.06)  | 2.57 (1.42–6.44)         | 2.56 (1.38–4.77)                  | 2.23 (1.36–3.63)                 | 1.82 (1.30–2.56)                           |
| Sensitivity analyses                       |       |                   |                          |                                   |                                  |                                             |
| All data, subset with data on HBV/HCV status| 100   | 2.83 (1.61–4.99)  | 2.62 (1.43–4.81)         | 2.88 (1.61–5.15)                  | 1.95 (1.24–3.06)                 | 1.83 (1.32–2.55)                           |
| Additionally adjusted for                  |       |                   |                          |                                   |                                  |                                             |
| Liver damage scoreb                        | 100   | 2.92 (1.02–8.40)  | 1.76 (0.83–3.72)         | 2.86 (1.03–7.92)                  | 1.41 (0.75–2.64)                 | 1.56 (0.96–2.51)                           |
| HBV/HCV status and liver damage scoreb     | 100   | 3.35 (0.82–13.77) | 1.66 (0.62–4.44)         | 2.35 (0.81–6.79)                  | 1.33 (0.64–2.77)                 | 1.60 (0.83–3.06)                           |

IRRs and 95% confidence intervals were estimated by conditional logistic regression conditioned on the matching factors and adjusted for smoking status (never, former, current), body mass index (continuous), baseline alcohol intake (continuous), coffee intake (continuous), lifetime alcohol drinking pattern (always heavy, periodically heavy, former heavy, never heavy, former light, light, and never drinker), physical activity (active, moderately active, moderately inactive, inactive), and level of education (none, primary school, secondary school, more than secondary school, not specified)

*aMean follow-up time among cases (6 years) was used as a cut-point

*bSubjects with liver damage score of 0 and 1 were considered to have normal liver function. Liver damage score ranges from 0 to 6, grouped in categories as 0, 1, ≥2 abnormal liver function tests based on the values provided by the laboratory: ALT >55 U/L, AST >34 U/L, GGT men >64 U/L, GGT women >36 U/L, AP >150 U/L, albumin <35 g/L, total bilirubin >1.2 mg/dL. Available for 100 cases and 100 controls
not statistically significant, likely because of the small number of female HCC cases. Nevertheless, the sex differences observed in our study might be biologically plausible, as men generally have lower innate and adaptive immune responses [47, 48], or because the gut microbiome may alter sex hormone levels and subsequently affect inflammation and autoantibody production, as has been observed in mice [49]. Another animal study has shown that LPS administration resulted in higher levels of LPS-binding protein and pro-inflammatory mediators in male compared to female mice [50]. Interestingly, we previously observed a similar sex-specific effect for endotoxemia associated with the development of colorectal cancer [51]. Future studies with larger numbers of women will be needed to confirm and better understand this potential effect modification by sex.

The main strength of our study is its prospective design, which allowed measurement of the biomarkers in blood samples collected in some cases many years prior to diagnosis. This implies a greater level of confidence in the hypothesis that higher LPS exposure and its various harmful effects are involved in early processes of HCC development. Nevertheless, higher LPS levels also may be indicative of a degree of liver dysfunction, since LPS-binding protein, which binds free circulating LPS, is synthesized in the liver, and individuals with a chronic liver disease may have altered hepatic endotoxin detoxification [52, 53]. Interestingly, the magnitude of our findings was not influenced by additional statistical adjustment for markers of liver dysfunction, further strengthening the argument for an early involvement of endotoxemia in HCC development. Other advantages of the present study are identification of HCC cases based on tumor morphology to ensure the inclusion of only first primary tumors. Research on HCC etiology is hampered by the rarity of the tumor, the inaccurate diagnosis and reporting of primary tumors since the liver is a major site for cancer metastases, and by metabolic changes that occur before cancer diagnosis. Therefore, this prospective study with long and almost complete follow-up, detailed information on dietary/lifestyle factors, and biomarkers measured before cancer diagnosis contributes considerably to our understanding of the role of gut-derived endotoxins in HCC etiology, and possibly HCC risk prediction. In this regard, our study may be criticized for its use of apparently healthy control subjects rather than those with non-HCC chronic liver diseases. But in our opinion, although the latter group may be informative for screening strategies targeted at individuals at higher risk of developing HCC, the former is the most appropriate for both our prospective cohort design and for our primary objective of investigating HCC etiology.

In terms of limitations, our results might be susceptible to confounding, since low LPS and flagellin immunoglobulin levels could indicate better lifestyle and health status. We have attempted to account for this with careful adjustment for relevant lifestyle habits (e.g., alcohol intake, smoking status, and diet), but we cannot discount possible residual confounding. Similarly, we cannot completely rule out the possibility of reverse causality due to the long-term nature of HCC development. We do not have data on incidence of type 2 diabetes and liver diseases (e.g., NAFLD or NASH) or on exposure to aflatoxins, which is uncommon in Western Europe [54]. Infections caused by Gram-negative bacteria of intestinal origin are common among persons with cirrhosis, especially those with more severe liver disease, and in in-hospital settings [55]. However, our study participants were generally healthy at the time of blood collection, and adjustments for biomarkers of liver damage or alcohol intake did not materially change the findings supporting the hypothesis that the presence of endotoxemia might be an additional factor contributing to liver carcinogenesis. In addition, obesity and diabetes, risk factors for HCC, have been shown to be associated with changes in the gut barrier function [56–58], which may contribute to HCC development outside of the spectrum of cirrhosis. However, a possibility that exposure to LPS may trigger the onset of obesity and insulin resistance was also suggested in animal models [59]. Finally, our sample size was relatively small, especially for assessing potential effect modifiers, and liver enzyme levels and HBV/HCV status were only available for 100 cases and 100 controls. Nevertheless, this is the largest prospective study to date on HCC etiology in Western European populations.

Conclusions
In summary, the findings from this prospective study are in line with the hypothesis that higher exposure to gut-derived endotoxins (due to impaired gut barrier function, lifestyle, or altered gut microbiome) is associated with higher risk of HCC.

Additional file

Additional file 1: Table S1. Baseline dietary intakes and blood biomarkers of incident HCC cases and matched control subjects within the European Prospective Investigation into Cancer and Nutrition (EPIC) study from 1992 to 2010. Table S2. Mean (95% CI) anti-LPS and anti-flagellin immunoglobulin levels in controls by sex, age at blood collection, and other baseline characteristics. Table S3. Incidence rate ratios and 95% confidence intervals of hepatocellular carcinoma according to categories of individual serum anti-LPS and anti-flagellin immunoglobulin levels, EPIC study, 1992–2010. (DOCX 35 kb)

Abbreviations
EPIC: European Prospective Investigation into Cancer and Nutrition; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; Ig: Immunoglobulin; LPS: Lipopolysaccharide; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis
Acknowledgements
The authors would like to thank C. Biessy and B. Hemon for their assistance in
database preparation. We are very grateful to Dr. E. Trepo for her assistance in
determination of hepatitis infection status, o-fetoprotein, and liver enzymes.
Reagents for the hepatitis infection determinations were kindly provided to
Labo Républice (Lyon, France) by Abbott Diagnostics Division, France.

Funding
This work was supported by the French National Cancer Institute (L’Institut
National du Cancer; INCA) (grant number 2009-139; Principal Investigator:
M. Jenab). The coordination of EPIC is financially supported by the European
Commission (DG-SANCO) and the International Agency for Research on
Cancer. The national cohorts are supported by the Danish Cancer Society
(Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale
de l’Education Nationale, and Institut National de la Santé et de la
Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutches
Krebsforschungszentrum, and Federal Ministry of Education and Research
(Germany); the Hellenic Health Foundation (Greece); the Sicilian Government,
AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul
Cancro-AIRC-Italy, and National Research Council (Italy); Dutch Ministry of Public
Health, Welfare and Sports (WWS), Netherlands Cancer Registry (NKR), LK
Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek
Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands
(the Netherlands); Nordic Centre of Excellence programme on Food, Nutrition
and Health (Norway); Health Research Fund (FIS), PI13/00616 to Granada,
Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no. 6236)
and Navarra, Regional Government of Asturias (Asturias, Spain), and ISCIII RETIC
(RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council, and
County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK
(14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford) and Medical Research
Council (1000143 to EPIC-Norfolk) (United Kingdom); and a Gridlers’ New
Zealand Health Research Council Fellowship (to Dr. K.E. Bradbury). The
funding sources had no influence on the design of the study; the collection,
analyis, and interpretation of data; the writing of the report; or the decision
in a European cohort: a nested case-control

Availability of data and materials
The datasets analyzed during the current study are available from the
non applicable.

Authors’ contributions
MJ and VF were responsible for the conception and design of this work;
all authors were responsible for data collection; VF for data analysis; and MJ for data interpretation and drafting of the article. All authors
provided critical revision of the article, and all authors read and approved the
final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Approval for this study was obtained from the IARC Ethics Committee
(Lyon, France) as well as from participating EPIC centers.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Author details
1Department of Epidemiology, Rollins School of Public Health, Emory
University, Atlanta, GA, USA. 2Winship Cancer Institute, Emory University,
Atlanta, GA, USA. 3Center for Inflammation, Immunity, and Infection Institute
for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
4Section of Nutrition and Metabolism, International Agency for Research on
Cancer (IARC-WHO), Lyon, France. 5Hellenic Health Foundation, 13 Kaisareias
Street, Athens GR-115 27, Greece. 6Department of Hygiene, Epidemiology and
Medical Statistics, WHO Collaborating Center for Nutrition and Health,
Unit of Nutritional Epidemiology and Nutrition in Public Health, University of
Athens Medical School, Athens, Greece. 7Department of Epidemiology,
German Institute of Human Nutrition Potsdam-Rehbruecke, Nutrition,
Immunology and Metabolism Start-up Lab, Nuthetal, Germany. 8Danish Cancer
Society Research Center, Copenhagen, Denmark. 9Section for Epidemiology,
Department of Public Health, Aarhus University, Aarhus, Denmark.
10Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif,
France. 11Gustave Roussy, Villejuif F-94805, France. 12Department of
Gastroenterology, Assistance Publique-Hôpitaux de Paris (AP-HP), University
hospitals Paris-Sud, Site de Bicêtre, Paris Sud University, Paris XI, Le Kremlin
Bicêtre, Villejuif, France. 13Human Genetics Foundation (HuGeF), Torino, Italy.
14Cancer Council Victoria and University of Melbourne, Melbourne, Australia.
15Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
Heidelberg, Germany. 16Department of Epidemiology, German Institute of
Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. 17Department of
Epidemiology, Harvard School of Public Health, Boston, MA, USA.
18Epidemiology and Prevention Unit Fondazione IFRCCS Istituto Nazionale dei
Tumori Via Venezian, 1 20133 Milano, Italy. 19Department of Medicina
Clinica Echirurgica Federico II University, Naples, Italy. 20Molecular and
Nutritional Epidemiology Unit, Cancer Research and Prevention Institute –
ISPO, Florence, Italy. 21Cancer Registry and Histopathology Unit, “Civic”–M.P.
Arezzo” Hospital, ASP, Ragusa, Italy. 22Molecular and Genetic Epidemiology
Unit, HuGeF, Human Genetics Foundation, Torino, Italy. 23Department of
Epidemiology, Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, the Netherlands. 24Department for
Determinants of Chronic Diseases (DCD), National Institute for Public Health
and the Environment (RWSM), Bilthoven, The Netherlands. 25Department of
Gastroenterology and Hepatology, University Medical Centre, Utrecht, The
Netherlands. 26Department of Epidemiology and Biostatistics, The School of
Public Health, Imperial College London, London, UK. 27Department of Social
& Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala
Lumpur, Malaysia. 28Department of Community Medicine, Faculty of Health
Sciences, University of Tromsø, The Arctic University of Norway, Tromsø,
Norway. 29Department of Research, Cancer Registry of Norway, Institute of
Population-Based Cancer Research, Oslo, Norway. 30Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
31Genetic Epidemiology Group, Folkhälsovård Research Center, Helsinki,
Finland. 32Department of Epidemiology, Murcia Regional Health Council,
IMIB-Arroaixa, Murcia, Spain. 33CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 34Navarra Public Health Institute, Pamplona, Spain.
35Navarra Institute for Health Research (IISNA), Pamplona, Spain. 36Escuela
Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada, Universidad de Granada,
Granada, Spain. 37Basque Regional Health Department, San Sebastian, Spain.
38Public Health Directorate, Asturias, Spain. 39Unit of Nutrition, Environment
and Cancer, Cancer Epidemiology Research Program, Catalan Institute of
Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. 40Department
of Clinical Sciences, Lund University, Malmö, Sweden. 41Department of
Gastroenterology and Nutrition, Skåne University Hospital, Malmö, Sweden.
42Department of Clinical Sciences, Division of Internal Medicine, Skåne
University Hospital, Malmö, Lund University, Lund, Sweden. 43Department of
Surgical and Perioperative Sciences, Kirurgcentrum, Norrsjöland,
Universitetssjukhus, Umeå, Sweden. 44Department of Medicine Sections for
Hepatology and Gastroenterology, Umeå University Hospital, SE-90185 Umeå,
Sweden. 45Cancer Epidemiology Unit, National Institute of Population
Health, University of Oxford, Oxford, UK. 46Clinical Gerontology Unit,
University of Cambridge School of Clinical Medicine, Cambridge, UK. 47Department
of Hygiene and Epidemiology, University of Ioannina School of Medicine,
Ioannina, Greece. 48Department of Epidemiology and Biostatistics, School
of Public Health, Imperial College London, London, UK.

Received: 13 September 2016 Accepted: 3 March 2017
Published online: 04 April 2017

References
1. McGlynn KA, London WT. The global epidemiology of hepatocellular
carcinoma: present and future. Clin Liver Dis. 2011;15(2):223–43, vii–x.
2. Trichopoulos D, Bania C, Lagiou P, et al. Hepatocellular carcinoma risk
factors and disease burden in a European cohort: a nested case-control
study. J Natl Cancer Inst. 2011;103(22):1686–95.
3. Fedirko V, Lukanova A, Barma C, et al. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol. 2013;24(2):543–53.

4. Zamora-Ros R, Fedirko V, Trichopoulou A, et al. Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European Prospective Investigation into Cancer and Nutrition study. Int J Cancer. 2013;133(10):2420–43.

5. Fedirko V, Trichopoulou A, Barma C, et al. Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Ann Oncol. 2013;24(8):2166–73.

6. Fedirko V, Duarte-Salles T, Barma C, et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology. 2014;60(4):1222–30.

7. Fedirko V, Duarte-Salles T, Barma C, et al. Alteration of amino acid and antioxidant capacity and risk of hepatocellular carcinoma in the European Prospective Investigation into Cancer and Nutrition. Hepatology. 2014;60(4):1222–30.

8. Fages A, Duarte-Salles T, Stepien M, et al. Metabolomic profiles of nonalcoholic steatohepatitis. J Nutr Biochem. 2015;26(11):1183–92.

9. Kulli KA, Hatonen KA, Lehto M, et al. Endotoxins, nutrition, and cardiometabolic disorders. Acta Diabetol. 2015;52(2):395–404.

10. Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver disease. Pediatr Res. 2013;73(1-2):245–51.

11. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94(6):2557–62.

12. Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571–9.

13. Xiao Y, Liu F, Yang J, et al. Over-activation of TLR5 signaling by high-dose flagellin induces liver injury in mice. Cell Mol Immunol. 2015;12(6):729–42.

14. Lincoln HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94(6):2557–62.

15. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

16. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94(6):2557–62.

17. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

18. Martinez-Mir L, Ferrer J, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;1:15.

19. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Clin Gastroenterol. 2011;45(2):149–52.

20. Thuy S, Ladumer R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with decreased plasma endotoxin and plasminogen activator inhibitor-1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452–5.

21. Vespasiani-Gentilucci U, Carotti S, Perrone G, et al. Hepatic toll-like receptor-4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Dig Dis Sci. 2012;57(7):1932–41.

22. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

23. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

24. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

25. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

26. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.

27. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic endotoxemia in nonalcoholic steatohepatitis. J Hepatol. 2015;62(1):57–64.
Cancer and Nutrition (EPIC) Cohort. Cancer Epidemiol Biomarkers Prev. 2016;25(2):291–301.

52. Shao B, Lu M, Katz SC, et al. A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen. J Biol Chem. 2007;282(18):13726–35.

53. Jirillo E, Caccavo D, Magrone T, et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res. 2002;8(5):319–27.

54. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818–24.

55. Botwin GJ, Morgan TR. Bacterial infections in cirrhosis. Hepatol Int. 2014;8 Suppl 2:467–74.

56. Gonzalez-Quintela A, Alonso M, Campos J, et al. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One. 2013;8(1):e54600.

57. Mohammed N, Tang L, Jahangiri A, et al. Elevated IgG levels against specific bacterial antigens in obese patients with diabetes and in mice with diet-induced obesity and glucose intolerance. Metabolism. 2012;61(9):1211–4.

58. Gummesson A, Carlsson LM, Storlien LH, et al. Intestinal permeability is associated with visceral adiposity in healthy women. Obesity (Silver Spring). 2011;19(11):2280–2.

59. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.